PDF(Pubmed)
Abstract：
UNASSIGNED: Gut microbiota influences energy homeostasis in part through circulating hormones. Insulin-like growth factor-binding protein (IGFBP)-2 is a biomarker whose increase in systemic circulation is associated with positive effects on body weight and metabolism. In a recent clinical trial, probiotic Lacticaseibacillus rhamnosus HA-114 supplementation showed positive effects on eating behaviors and insulin resistance in overweight participants undergoing a weight-loss intervention. In this context, this ancillary study aimed at assessing the impact of L. rhamnosus HA-114 supplementation on plasma IGFBP-2 levels in these individuals, and whether this modulation correlated with changes in fat mass, energy metabolism, and eating behaviors.
UNASSIGNED: Fasting plasma IGFBP-2 concentrations were quantified in 100 overweight or obese men and women enrolled in a 12-week diet-based weight reduction program (-500 kcal/day), in combination with probiotic L. rhamnosus HA-114 or placebo supplementation. Baseline and changes in circulating IGFBP-2 concentrations were correlated with anthropometric parameter, glucose and lipid metabolism, cardiorespiratory function and eating behaviors.
UNASSIGNED: On average, the intervention reduced BMI by 4.6 % and increased IGFBP-2 by 13 %, regardless of supplementation group. Individuals who presented an increase in IGFBP-2 levels had significantly greater reductions in BMI. Changes in IGFBP-2 levels were correlated with loss in fat mass (r = 0.2, p < 0.001) in the probiotic-supplemented group, but not with other metabolic parameters or eating behaviors. Baseline IGFBP-2 levels were not associated with weight loss or improvements in cardiometabolic parameters.
UNASSIGNED: Probiotic supplementation with L. rhamnosus HA-114 did not modulate plasma IGFBP-2 levels. Changes in IGFBP-2 levels were correlated with greater reductions in BMI, but not with other metabolic parameters or eating behaviors, indicating that the benefits of HA-114 on eating behaviors are likely independent of IGFBP-2. Additional changes in microbiota might be required to modulate IGFBP-2 and observe its associations with eating behaviors and cardiometabolic improvements.
UNASSIGNED: Fasting plasma IGFBP-2 concentrations were quantified in 100 overweight or obese men and women enrolled in a 12-week diet-based weight reduction program (-500 kcal/day), in combination with probiotic L. rhamnosus HA-114 or placebo supplementation. Baseline and changes in circulating IGFBP-2 concentrations were correlated with anthropometric parameter, glucose and lipid metabolism, cardiorespiratory function and eating behaviors.
UNASSIGNED: On average, the intervention reduced BMI by 4.6 % and increased IGFBP-2 by 13 %, regardless of supplementation group. Individuals who presented an increase in IGFBP-2 levels had significantly greater reductions in BMI. Changes in IGFBP-2 levels were correlated with loss in fat mass (r = 0.2, p < 0.001) in the probiotic-supplemented group, but not with other metabolic parameters or eating behaviors. Baseline IGFBP-2 levels were not associated with weight loss or improvements in cardiometabolic parameters.
UNASSIGNED: Probiotic supplementation with L. rhamnosus HA-114 did not modulate plasma IGFBP-2 levels. Changes in IGFBP-2 levels were correlated with greater reductions in BMI, but not with other metabolic parameters or eating behaviors, indicating that the benefits of HA-114 on eating behaviors are likely independent of IGFBP-2. Additional changes in microbiota might be required to modulate IGFBP-2 and observe its associations with eating behaviors and cardiometabolic improvements.
摘要：
■肠道菌群部分通过循环激素影响能量稳态。胰岛素样生长因子结合蛋白（IGFBP）-2是一种生物标志物，其体循环的增加与对体重和代谢的积极影响有关。在最近的临床试验中，补充益生菌鼠李糖乳杆菌HA-114对接受减肥干预的超重参与者的饮食行为和胰岛素抵抗显示出积极作用.在这种情况下，这项辅助研究旨在评估补充鼠李糖乳杆菌HA-114对这些个体血浆IGFBP-2水平的影响，以及这种调节是否与脂肪量的变化相关，能量代谢，和饮食行为。
■对参加12周基于饮食的减肥计划（-500千卡/天）的100名超重或肥胖男性和女性的空腹血浆IGFBP-2浓度进行了定量，与益生菌鼠李糖乳杆菌HA-114或安慰剂补充剂组合。基线和循环IGFBP-2浓度的变化与人体测量参数相关，葡萄糖和脂质代谢，心肺功能和饮食行为。
■平均而言，干预措施使BMI降低了4.6%，IGFBP-2增加了13%，无论补充组。IGFBP-2水平升高的个体的BMI降低幅度更大。在补充益生菌的组中，IGFBP-2水平的变化与脂肪量的减少相关（r=0.2，p<0.001），但与其他代谢参数或饮食行为无关。基线IGFBP-2水平与体重减轻或心脏代谢参数改善无关。
■补充鼠李糖乳杆菌HA-114的益生菌不调节血浆IGFBP-2水平。IGFBP-2水平的变化与BMI的降低有关，但与其他代谢参数或饮食行为无关，表明HA-114对饮食行为的益处可能独立于IGFBP-2。可能需要微生物群的其他变化来调节IGFBP-2并观察其与进食行为和心脏代谢改善的关联。
■对参加12周基于饮食的减肥计划（-500千卡/天）的100名超重或肥胖男性和女性的空腹血浆IGFBP-2浓度进行了定量，与益生菌鼠李糖乳杆菌HA-114或安慰剂补充剂组合。基线和循环IGFBP-2浓度的变化与人体测量参数相关，葡萄糖和脂质代谢，心肺功能和饮食行为。
■平均而言，干预措施使BMI降低了4.6%，IGFBP-2增加了13%，无论补充组。IGFBP-2水平升高的个体的BMI降低幅度更大。在补充益生菌的组中，IGFBP-2水平的变化与脂肪量的减少相关（r=0.2，p<0.001），但与其他代谢参数或饮食行为无关。基线IGFBP-2水平与体重减轻或心脏代谢参数改善无关。
■补充鼠李糖乳杆菌HA-114的益生菌不调节血浆IGFBP-2水平。IGFBP-2水平的变化与BMI的降低有关，但与其他代谢参数或饮食行为无关，表明HA-114对饮食行为的益处可能独立于IGFBP-2。可能需要微生物群的其他变化来调节IGFBP-2并观察其与进食行为和心脏代谢改善的关联。
